Melinta To Launch First Commercial Drug Baxdela Independently

Melinta is positioning its novel fluroquinolone antibiotic as an attractive option for seriously ill patients with underlying chronic conditions, but Baxdela will face challenges in a market dominated by generics.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.

Melinta Therapeutics Inc. will sell its first commercial drug – the antibiotic Baxdela (delafloxacin) – independently through a hospital-based commercial organization that is in the process of being built, according to CEO Eugene Sun.

FDA approved the fluoroquinolone antibiotic June 19 for the treatment of acute bacterial skin and skin structure infections (ABSSI) in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip